Trump's 100% Tariff Threat: Pharmaceutical Shake-Up

The Trump administration announced a dramatic move on Thursday, threatening to impose a 100% tariff on imported branded pharmaceuticals unless manufacturers agree to specific drug pricing deals or shift production to the United States.

This measure aims to push drugmakers towards onshore production while attempting to reduce the soaring prices of U.S. prescriptions. Exemptions and reduced rates can be accessed through compliance with trade agreements, manufacturing commitments, and favored-nation pricing pacts.

The policy affords 120 days for large pharmaceutical companies and 180 days for smaller ones to strategize, with several big providers like Pfizer and Eli Lilly already securing exemptions by signing deals. Meanwhile, debates over pricing frameworks and international tariffs continue to stir the industry.